drugset / Trial / NCT02434497

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

NCT02434497

Phase 3 Completed 9 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.

Timeline

Start
2015-06-06
Primary completion
2016-11-17
Completion
2016-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Rosuvastatin Small molecule 40 mg Oral